RGD dendron bodies; synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies

Daniel Q. McNerny, Jolanta F. Kukowska-Latallo, Douglas G. Mullen, Joseph M. Wallace, Ankur M. Desai, Rameshwer Shukla, Baohua Huang, Mark M. Banaszak Holl, James R. Baker

Research output: Contribution to journalArticleResearchpeer-review

34 Citations (Scopus)


Poly(amidoamine) (PAMAM) dendrons were synthesized with c(RGDyK) peptide on the surface to create a scaffold for cellular targeting and multivalent binding. Binary dendron-RGD conjugates were synthesized with a single Alexa Fluor 488, biotin, methotrexate drug molecule, or additional functionalized dendron at the focal point. The targeted dendron platform was shown to specifically target αVβ3 integrin expressing human umbilical vein endothelial cells (HUVEC) and human glioblastoma cells (U87MG) in vitro via flow cytometry. Specific targeting of the dendron-RGD platform was further confirmed by confocal microscopy. Biological activity of the targeted drug conjugate was confirmed via XTT assay. The orthogonal reaction chemistry used at the dendron focal point gives a precise 1:1 ratio of the attachment of multiple functionalities to a small-molecular-weight, chemically stable, high avidity molecule. These studies serve as a framework to selectively combine biologically relevant functions with enhanced specific binding activity to substitute for antibodies in many diagnostic and therapeutic applications.

Original languageEnglish
Pages (from-to)1853-1859
Number of pages7
JournalBioconjugate Chemistry
Issue number10
Publication statusPublished - 21 Oct 2009
Externally publishedYes

Cite this